EGFR and non-small cell lung carcinoma: EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, erlotinib, afatinib, dacomitinib and osimertinib have been used to treat NSCLC, and extremely good responses have been achieved in EGFR mutated NSCLC patients.19